📌 At a Glance
Dabur India’s share price has flatlined around ₹490 despite being one of India’s most iconic FMCG names. Over the last 5 years (FY21 to FY25), revenue climbed from ₹9,562 Cr to ₹12,563 Cr — just a 31% rise, or 5.6% CAGR. Meanwhile, profit barely moved from ₹1,695 Cr to ₹1,740 Cr. The stock’s P/E still hovers near 50, and working capital days exploded to 61. So… is Dabur still the king of Ayurveda? Or just drinking its own Chyawanprash?
🧬 About the Company
- Dabur India Ltd, founded in 1884, is one of the oldest FMCG companies in India.
- It’s the largest Ayurvedic and Natural Healthcare brand globally, with 250+ products in categories like health supplements, personal care, oral care, and home care.
- Its top brands include Dabur Chyawanprash, Dabur Honey,
- Real Juices, and Vatika.
👨💼 Key Managerial Personnel (KMP)
| Name | Designation |
|---|---|
| Mohit Malhotra | CEO & Whole Time Director |
| Amit Burman | Chairman |
| Sudhanshu Vats | CEO, Dabur International |
| Ashok Jain | CFO |
CEO Mohit Malhotra has been steering the company through a slow-growth FMCG era, with an emphasis on premiumization and rural push.
📊 5-Year Financial Recap (FY21–FY25)
| Financial Year | Revenue (₹ Cr) | Net Profit (₹ Cr) | EPS (₹) | OPM % | ROCE % | Dividend Payout % |
|---|---|---|---|---|---|---|
| FY21 | 9,562 | 1,695 | 9.58 | 21% | 27% | 50% |
| FY22 | 10,889 | 1,742 | 9.84 | 21% | 27% | 53% |
| FY23 | 11,530 | 1,701 | 9.64 | 19% | 23% | 54% |
| FY24 | 12,404 | 1,811 | 10.40 | 19% | 22% | 53% |
| FY25 | 12,563 | 1,740 | 9.97 | 18% | 20% | 80% |
➡️ Revenue up 31% in 5 years.
➡️ Net profit barely up 2.6% over 5 years.
➡️ ROCE declining, Dividend payout shooting up (sign of slowdown?).
📉 Margin Compression & Cash Flow Woes
- Operating margins slipped from 21% to 18%.
- ROCE dropped from a healthy 27%
To Read Full 16 Point ArticleBecome a member